Corrigendum to “Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis” [Lung Cancer 68 (1) (2010) 27–38](S0169500209002669)(10.1016/j.lungcan.2009.05.014);Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 27-38

  Zhuang, Hongqin ^a   Jiang, Weiwei ^a   Cheng, Wei ^a   Qian, Kui ^a   Dong, Wei ^a,b   Cao, Lin ^a   Huang, Qilai ^a   Li, Shufeng ^a,c   Dou, Fei ^c   Chiu, Jen Fu ^a,d   Fang, Xue Xun ^a,e   Lu, Min ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e JILIN UNIVERSITY   (China)

Author keywords

A549 cell; Apoptosis; HSP27; Non small cell lung cancer; RNA interference; Sensitivity; TRAIL

Indexed keywords

HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN P53; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

EID: 77649191803     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2020.01.003     Document Type: Erratum

References (83)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
2. Dominioni L., Imperatori A., Rovera F., Ochetti A., Torrigiotti G., and Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer 89 (2000) 2334-2344
3. Ferguson M.K. Diagnosing and staging of non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 4 (1990) 1053-1068
4. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
5. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
6. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
7. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64 (2004) 4900-4905
8. Ray S., and Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63 (2003) 4713-4723
9. Shankar S., Singh T.R., Chen X., Thakkar H., Firnin J., and Srivastava R.K. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int. J. Oncol. 24 (2004) 1133-1140
10. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2 (2003) 1273-1284
11. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
12. Desagher S., and Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10 (2000) 369-377
13. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
14. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
15. Chao D.T., and Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16 (1998) 395-419
16. Colo G.P., Rosato R.R., Grant S., and Costas M.A. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett. 581 (2007) 5075-5081
17. Ozoren N., and El Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp. Cell Res. 281 (2002) 175-181
18. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
19. Zhang L., and Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12 (2005) 228-237
20. Eid M.A., Lewis R.W., Abdel-Mageed A.B., and Kumar M.V. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int. J. Oncol. 21 (2002) 111-117
21. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17 (2003) 1794-1805
22. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 23 (2004) 4993-5003
23. Jazirehi A.R., Ng C.P., Gan X.H., Schiller G., and Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin. Cancer Res. 7 (2001) 3874-3883
24. Tillman D.M., Izeradjene K., Szucs K.S., Douglas L., and Houghton J.A. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res. 63 (2003) 5118-5125
25. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248 (1999) 30-43
26. Bostwick D.G. Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol. Urol. 4 (2000) 101-106
27. Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60 (2000) 7099-7105
28. Conroy S.E., Sasieni P.D., Amin V., Wang D.Y., Smith P., Fentiman I.S., et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br. J. Cancer 77 (1998) 1875-1879
29. Arts H.J., Hollema H., Lemstra W., Willemse P.H., De Vries E.G., Kampinga H.H., et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int. J. Cancer 84 (1999) 234-238
30. Malusecka E., Zborek A., Krzyzowska-Gruca S., and Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res. 21 (2001) 1015-1021
31. Kapranos N., Kominea A., Konstantinopoulos P.A., Savva S., Artelaris S., Vandoros G., et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J. Cancer Res. Clin. Oncol. 128 (2002) 426-432
32. Bruey J.M., Ducasse C., Bonniaud P., Ravagnan L., Susin S.A., Diaz-Latoud C., et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2 (2000) 645-652
33. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
34. Charette S.J., Lavoie J.N., Lambert H., and Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol. Cell Biol. 20 (2000) 7602-7612
35. Concannon C.G., Orrenius S., and Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Exp. 9 (2001) 195-201
36. Garrido C., Bruey J.M., Fromentin A., Hammann A., Arrigo A.P., and Solary E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 13 (1999) 2061-2070
37. Havasi A., Li Z., Wang Z., Martin J.L., Botla V., Ruchalski K., et al. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J. Biol. Chem. 283 (2008) 12305-12313
38. Pandey P., Farber R., Nakazawa A., Kumar S., Bharti A., Nalin C., et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19 (2000) 1975-1981
39. O'Callaghan-Sunol C., Gabai V.L., and Sherman M.Y. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 67 (2007) 11779-11788
40. Venkatakrishnan C.D., Dunsmore K., Wong H., Roy S., Sen C.K., Wani A., et al. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1736-H1744
41. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998) 1322-1326
42. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
43. Beere H.M., and Green D.R. Stress management-heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol. 11 (2001) 6-10
44. Xanthoudakis S., and Nicholson D.W. Heat-shock proteins as death determinants. Nat. Cell Biol. 2 (2000) E163-E165
45. Aghdassi A., Phillips P., Dudeja V., Dhaulakhandi D., Sharif R., Dawra R., et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 67 (2007) 616-625
46. Conroy S.E., and Latchman D.S. Do heat shock proteins have a role in breast cancer?. Br. J. Cancer 74 (1996) 717-721
47. Garrido C., Fromentin A., Bonnotte B., Favre N., Moutet M., Arrigo A.P., et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 58 (1998) 5495-5499
48. Morino M., Tsuzuki T., Ishikawa Y., Shirakami T., Yoshimura M., Kiyosuke Y., et al. Specific expression of HSP27 in human tumor cell lines in vitro. In Vivo 11 (1997) 179-184
49. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
50. Dong W., Jin G.H., Li S.F., Sun Q.M., Ma D.Y., and Hua Z.C. Cross-linked polyethylenimine as potential DNA vector for gene delivery with high efficiency and low cytotoxicity. Acta Biochim. Biophys. Sin. (Shanghai) 38 (2006) 780-787
51. Cao L., Du P., Jiang S.H., Jin G.H., Huang Q.L., and Hua Z.C. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 7 (2008) 851-861
52. Aydin C., Sanlioglu A.D., Karacay B., Ozbilim G., Dertsiz L., Ozbudak O., et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum. Gene Ther. 18 (2007) 39-50
53. Jin C.Y., Moon D.O., Lee J.D., Heo M.S., Choi Y.H., Lee C.M., et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis 28 (2007) 1058-1066
54. Li S., Dong W., Zong Y., Yin W., Jin G., Hu Q., et al. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol. Ther. 15 (2007) 515-523
55. Qian F., Li Y.P., Sheng X., Zhang Z.C., Song R., Dong W., et al. PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol. Med. 13 (2007) 151-159
56. Ozoren N., and El Deiry W.S. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 13 (2003) 135-147
57. Ivanov V.N., and Hei T.K. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp. Cell Res. 312 (2006) 4120-4138
58. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 94 (2003) 1066-1073
59. Peto R., Lopez A.D., Boreham J., Thun M., Heath Jr. C., and Doll R. Mortality from smoking worldwide. Br. Med. Bull. 52 (1996) 12-21
60. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
61. Fulda S., and Debatin K.M. Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta 1705 (2004) 27-41
62. Hao C., Song J.H., Vilimanovich U., and Kneteman N.M. Modulation of TRAIL signaling complex. Vitam. Horm. 67 (2004) 81-99
63. Hersey P., and Zhang X.D. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer 1 (2001) 142-150
64. Ma Y., Lakshmikanthan V., Lewis R.W., and Kumar M.V. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 5 (2006) 170-178
65. Panner A., Murray J.C., Berger M.S., and Pieper R.O. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res. 67 (2007) 9482-9489
66. Beere H.M., Wolf B.B., Cain K., Mosser D.D., Mahboubi A., Kuwana T., et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. 2 (2000) 469-475
67. Paul C., Manero F., Gonin S., Kretz-Remy C., Virot S., and Arrigo A.P. Hsp27 as a negative regulator of cytochrome C release. Mol. Cell Biol. 22 (2002) 816-834
68. Langdon S.P., Rabiasz G.J., Hirst G.L., King R.J., Hawkins R.A., Smyth J.F., et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin. Cancer Res. 1 (1995) 1603-1609
69. Lemieux P., Oesterreich S., Lawrence J.A., Steeg P.S., Hilsenbeck S.G., Harvey J.M., et al. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 17 (1997) 113-123
70. Aloy M.T., Hadchity E., Bionda C., Diaz-Latoud C., Claude L., Rousson R., et al. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 543-553
71. Kamada M., So A., Muramaki M., Rocchi P., Beraldi E., and Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 6 (2007) 299-308
72. Appasani K. RNA interference technology in drug validation and development: RNomics approach. Pharmacogenomics 5 (2004) 19-23
73. Nganvongpanit K., Muller H., Rings F., Gilles M., Jennen D., Holker M., et al. Targeted suppression of E-cadherin gene expression in bovine preimplantation embryo by RNA interference technology using double-stranded RNA. Mol. Reprod. Dev. 73 (2006) 153-163
74. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.P., and Rubinsztein D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11 (2002) 1137-1151
75. Rane M.J., Pan Y., Singh S., Powell D.W., Wu R., Cummins T., et al. Heat shock protein 27 controls apoptosis by regulating Akt activation. J. Biol. Chem. 278 (2003) 27828-27835
76. Parcellier A., Schmitt E., Gurbuxani S., Seigneurin-Berny D., Pance A., Chantome A., et al. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol. Cell Biol. 23 (2003) 5790-5802
77. Certo M., Del G.M., Nishino V., Wei M., Korsmeyer G., Armstrong S.A., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
78. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin. Oncol. 33 (2006) 449-456
79. Chang L., Kamata H., Solinas G., Luo J.L., Maeda S., Venuprasad K., et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124 (2006) 601-613
80. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161 (1998) 2833-2840
81. Ivanov V.N., Partridge M.A., Johnson G.E., Huang S.X., Zhou H., and Hei T.K. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell Res. 314 (2008) 1163-1176
82. Gong B., Chen Q., Endlich B., Mazumder S., and Almasan A. Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases. Cell Growth Differ. 10 (1999) 491-502
83. Wu G.S., Burns T.F., McDonald III E.R., Jiang W., Meng R., Krantz I.D., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17 (1997) 141-143